Clinical Trial Update: Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial comparing doxorubicin hydrochloride to trabectedin for previously untreated advanced or metastatic soft tissue sarcoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• DOXORUBICIN HYDROCHLORIDE (Doxorubicin hydrochloride)
• Trabectedin (trabectedin)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Sarcoma | Phase 2, Phase 3 | Status: TERMINATED